Autolus Therapeutics plc EBITDA 2011-2026 | AUTL

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Autolus Therapeutics plc

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-262 M	-234 M	-173 M	-136 M	-133 M	-162 M	-141 M	-23.3 M	-22.4 M	-13.9 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-13.9 M	-262 M	-130 M

Quarterly EBITDA Autolus Therapeutics plc

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-69.5 M	-59.1 M	-63.2 M	-66 M	-57 M	-37 M	-41.5 M	-42.9 M	-37.2 M	-	-41.7 M	-	-	-	-	-	-38.2 M	-	-41.2 M	-38.3 M	-37.3 M	-	-34.5 M	-36.1 M	-28.5 M	-24.4 M	300 K	500 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
500 K	-69.5 M	-39.6 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
AbbVie ABBV	15.8 B	$ 208.84	-2.86 %	$ 369 B	USA
AbCellera Biologics ABCL	-199 M	$ 3.52	0.28 %	$ 1.05 B	Canada
Grifols, S.A. GRFS	595 M	$ 8.24	-0.12 %	$ 6.83 B	Spain
Ascendis Pharma A/S ASND	-452 M	$ 229.25	0.44 %	$ 5 B	Danmark
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
ANI Pharmaceuticals ANIP	68.3 M	$ 74.21	-2.3 %	$ 1.43 B	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
Cocrystal Pharma COCP	-8.95 M	$ 1.51	48.04 %	$ 17 M	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
BioMarin Pharmaceutical BMRN	489 M	$ 55.5	-3.04 %	$ 10.6 B	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	-50.6 M	-	10.36 %	$ 9.8 M	USA
Arcturus Therapeutics Holdings ARCT	-73.2 M	$ 8.03	2.29 %	$ 220 M	Israel
Adaptive Biotechnologies Corporation ADPT	-41.1 M	$ 14.81	2.63 %	$ 2.25 B	USA
Altimmune ALT	-94.4 M	$ 3.34	7.05 %	$ 294 M	USA
BioNTech SE BNTX	15.3 B	$ 91.18	1.97 %	$ 27.2 B	Germany
Amgen AMGN	14.2 B	$ 347.94	-1.51 %	$ 187 B	USA
Aurinia Pharmaceuticals AUPH	52.7 M	$ 15.61	0.9 %	$ 2.1 B	Canada
Bristol-Myers Squibb Company BMY	4.01 B	$ 59.6	-2.45 %	$ 121 B	USA
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Burford Capital Limited BUR	242 M	$ 4.14	-2.59 %	$ 683 M	Britain
BioCryst Pharmaceuticals BCRX	-1.3 M	$ 9.02	-3.84 %	$ 1.86 B	USA
Avenue Therapeutics ATXI	-3.08 M	-	-52.27 %	$ 4.45 M	USA
Atea Pharmaceuticals AVIR	-180 M	$ 5.76	1.95 %	$ 469 M	USA
BeiGene, Ltd. BGNE	589 M	-	0.49 %	$ 251 B	Cayman-islands
AVROBIO AVRO	10.8 M	-	1083.1 %	$ 745 M	USA
Cellectis S.A. CLLS	-131 M	$ 3.41	1.19 %	$ 116 M	France
Biogen BIIB	780 M	$ 177.34	-3.5 %	$ 26 B	USA
Axcella Health AXLA	-76.6 M	-	-16.42 %	$ 249 M	USA
Axon Enterprise AXON	107 M	$ 412.81	-2.54 %	$ 31.3 B	USA